The atypical opioid, tramadol, has recently been introduced into Australia and New Zealand. Tramadol's efficacy in a wide range of acute and chronic pain states, its multi-formulation availability, and its low serious side-effect potential at high doses and in prolonged therapy, combine to bestow on it a user-friendly profile, for short-and long-term use in hospitals and communities. This paper reviews the following: its formulation and routes of administration; its unique enantiomeric biochemistry and metabolism; its triple mechanisms of action; its pharmacokinetics and pharmacodynamics; its analgesic efficacy compared with other opioids; the indications for its clinical use in a variety of acute and chronic (including cancer) painful states; its specific use in the elderly, in paediatric and in obstetric patients; its adverse event (including drug interaction) and safety profile; its advantages in terms of its relative lack of respiratory depression, major organ toxicity and histamine release, and dependence and abuse potential. The review looks at new uses for this drug and what can be expected in this area in the future.
Among the atypical central-acting opioids is tramadol hydrochloride. Tramadol [tramadol hydrochloride:(1RS, 2RS)-2-[(dimethylamine) methyl-1-(3 methoxyphenyl)-cyclohexanol HCl] is a synthetic 4-phenyl-piperidine analogue of codeine 1 . It is thus an aminocyclohexonol derivative 2 . It was synthesized by Drs Flick and Frankus at Grunenthal Research Laboratories in Aachen, Germany in 1962 3 . It entered the West German market in 1977 as a 100 mg (2 ml) ampoule in 1977 2 . It is the most widely sold opioid analgesic in the world and is registered and marketed in more than 100 countries 3 . It is the most recently introduced analgesic in many countries (e.g., Australia, New Zealand) 4, 5 . Throughout the world, more than 50 million patients have received tramadol and hence a large pool of knowledge has been gathered concerning its behaviour both in terms of efficacy and safety 2, 4, 5 . Initially, it received a mixed reception, as there were reports of intraoperative awareness, convulsions and possible interactions with coumarins 2, 6, 7 . Tramadol was considered to be a weak atypical opioid 6 . However, new evidence now clarifies both its analgesic mechanism and clinical application.
PHARMACOKINETICS
In terms of human pharmacokinetics, the oral absorption of tramadol in the upper small intestine is 95 to 100%, and the bioavailability is 70% following single doses (due to an approximately 30% first pass metabolism) and 90% in multiple dose studies with a steady state being reached in 36 hours 2, 8, 9, 10 .
After oral administration it is rapidly absorbed, with peak serum concentrations reached within two hours for capsules and five hours for sustained release tablets 1, 8 . There is 1% placental transfer 8 with 0.1% of the dose reaching breast milk 2 . Tramadol has a high tissue affinity with a volume of distribution of 306 and 203 litres after oral and intravenous (IV) administration, respectively 8 . Approximately 20% is protein-bound 11 . The elimination pharmacokinetics of tramadol are appropriately described by a twocompartment model, with a reported elimination half-life (T 1 ¼ 2E ) of 5.1 (SD±0.8) hours (h) for tramadol, and 9 h for the Metabolite 1 (M1) derivative after a single oral dose of 100 mg 1, 12 . This explains the approximately twofold accumulation of the parent drug and its M1 derivative that is observed during multiple dose treatment with tramadol 1 .
Tramadol sustained release capsules (50, 100, 200 mg) have shown dose-linearity in healthy volunteers 13 . Statistical analysis of the Area Under the Curve (AUC, 0-infinity) and C max after logarithmic transformation yielded bioequivalence with or without concomitant food intake 14 . As a result of statistical analysis of AUCs (48-72 h) after logarithmic transformation, the bioavailability of the sustained release capsules was calculated as equivalent to that of the instant release capsules 15 .
Eighty-six per cent of absorbed tramadol is metabolized in the liver and 90% of tramadol and its metabolites are excreted by the kidneys, with the residual in the faeces 8, 16, 17 . Less than 1% of tramadol is eliminated by biliary excretion 2 . The enantiomeric ratios of all the excreted analytes, tramadol, M1, M2 and M5 are found to be very different from 1.0, showing that a stereoselective metabolism of tramadol occurs 16 . Consequently, malfunction of either organ (liver or kidney) may affect plasma levels. In these situations, it is recommended that the total dose of tramadol be halved, but the dosage interval be increased (e.g., to 200 mg/day in 12-hourly divided doses in chronic renal failure, and to 50 mg every 12 hours with hepatic cirrhosis) 2, 8, 18 . Four hours of dialysis removes less than 7% of tramadol and M1 2 . With drug-induced hepatic enzyme induction, its dose can be doubled 8 .
The oral administration of tramadol is comparable to the intramuscular (IM) injection both in time to analgesic onset and to peak plasma levels 1 . The recommended oral daily dose is between 50 and 100 mg every four to six hours 1 . The duration of analgesia is about six hours after a single oral dose of 100 mg 1 . Tramadol is rapidly absorbed after IM injection, making the IM injection (50 mg) bioequivalent (with respect to the extent of systemic availability) to the 30-minute (50 mg) IV infusion 19 . The differences in the times of onset and duration of action expected due to the slightly slower absorption after IM injection are small and probably therapeutically irrelevant 19 .
PHARMACOLOGY (a) Mechanism of Action
Tramadol possesses a weak affinity for the mu-opioid receptor, and even less for the kappa and delta 5 . This affinity is some 6000 times less than that of morphine, 100-fold less than dextropropoxyphene, 10-fold less than codeine, and equivalent to dextromethorphan 2,20-23 . The (+) enantiomer of tramadol and its metabolites bind more strongly to the mu-opioid receptors than the respective (-) enantiomers 3 .
The opioid and 5-hydroxy tryptamine (5-HT or serotonin) reuptake inhibitory effect (increasing the central neuronal synaptic 5-HT levels and displacing stored 5-HT from nerve endings), is about four times more potent in the (+) enantiomer 24 . There is also a presynaptic stimulation of 5-HT release 3, 6, 20, 25, 26 . The noradrenaline (NA) reuptake inhibitory effect is in the (-) enantiomer, which also causes increased stimulation-evoked release by pre-synaptic autoreceptor activation 2, 3, 20, 25, 27 . By its ability to block these uptake mechanisms, tramadol elevates the central synaptic levels of noradrenaline and 5-HT, the former acting via alpha-2 adrenoceptor mechanisms, the latter via unknown receptors to reduce excitability of spinal nociceptive activity 3 . A recent study with rat brain cortical synaptosomes indicates that tramadol is a 5-HT uptake blocker 28 . The activity of tramadol is only partially reversed with naloxone (about 30%) 29 . 5-HT antagonists (rianserin), as well as alpha-2 adrenoceptor antagonists (yohimbine), will remove the remainder 30, 31 . Tramadol achieves spinal modulation of pain through indirect activation of postsynaptic alpha-2 adrenoceptors, preventing impulses from reaching the brain 8 . There is strong evidence for a synergistic interaction between the mu-opioid receptors and the alpha-2 adrenoceptors 3 . As these are independent receptors sharing common effector mechanisms, a supra-additive inhibitory action results from the simultaneous activation of the two receptors 3 . The uptake inhibition in both the non-opioid and opioid systems takes place in the same concentration range (0.5-50 µM) 2 . Thus, the overall analgesic action of tramadol results from multiple pharmacological mechanisms of opioid and nonopioid actions, such that the degree of pain relief is greater than the sum of the individual components of its action.
The complementary and synergistic mode of action of these two enantiomers is both opioid and monoaminergic (extending the analgesic effect to both opioid sensitive and insensitive pain); this synergism results in a significant reduction in the sideeffect profile typically associated with opioids, thus enhancing the safety profile of tramadol 1, 3, 8, 32 . The racemate seems to have superior efficacy and safety when compared to either enantiomer, (+) or (-) 33 .
Using straightforward molecular modelling techniques, the preference of the enantiomers of tramadol and its metabolites for binding at the mu-opioid receptor and the noradrenaline-uptake transporter can be understood in light of the different three-dimensional arrangements of the pharmacophores in comparison to morphine and to noradrenaline 3 .
(b) Metabolism
Tramadol is metabolized by a polymorphic isoenzyme of the debrisoquine-type, cytochrome P450 2D6 (CYP2D6) or sparteine oxygenase 1, 3, 4 , to 11 metabolites. Of the 11 metabolites, five arise from phase I reactions (M1 to M5) and six by phase II conjugation reactions (glucuronides and sulphates of M1, M4, and M5) 17 . The phase I metabolites are mono-Ode(s)methyl-tramadol or M1 (the only pharmacologically active metabolite), mono-N-demethyl tramadol (M2), di-N-demethyl tramadol (M3), tri-N, O-demethyl tramadol (M4), and di-N,O-demethyl tramadol (M5) 17, 35 . The M1 and M1-conjugates, M5 and M5-conjugates, and M2 are the main metabolites, whereas M3, M4, and M4-conjugates are formed only in minor quantities 17 , of which the active (analgesic) metabolite, mono-O-de(s)methyl tramadol (M1) predominates 6 . Both M1 and M5 bind to the opioid receptor 3 . M1 has a greater (200 fold) affinity for the mu-opioid receptor than does tramadol itself 1, 36 , but clinically, plays the minor role in the production of analgesia (while M5 has no analgesic role) 3 . About one third of the dose is metabolized to the O-de(s)methylated metabolites (+) and (-)M1 by CYP2D6 catalysation 3 . This enzyme exhibits genetic polymorphism. It is present in 93% of the population (extensive metabolizers of the drug sparteine) and absent in 7% (poor metabolizers or PMS) 3 . It can be inhibited by different drugs (e.g., quinidine) 3 . The selective O-de(s)methylation of tramadol via CYP2D6 can be used to study the contribution of the monoaminergic effect of tramadol and the opioid effect of (+)-M1 to the analgesic effect of tramadol. It has been concluded that (+)-M1 contributes to the analgesic effect of tramadol in experimental pain and probably also in clinical pain 3 . However, the analgesic effect of tramadol seems to depend on both the monoaminergic effects of tramadol itself and the opioid effect of (+)-M1, since the analgesic effect is reduced, but not completely abolished, in poor metabolizers that are unable to form (+)-M1 from tramadol 3 . Tramadol has been found to reduce IV propofol injection pain 37 . A peripheral analgesic effect of tramadol is postulated 37 .
(c) Preparations Available
The drug is available in formulations suitable for oral, rectal, and parenteral (IM and IV) administration 4, 5 . The marketed formulations of tramadol contain a racemic mixture of two enantiomers (50:50), each one displaying differing affinities for various receptors, yet each separately producing a dose-dependent central-mediated antinociception 1, 3 . It is available as capsules (50 mg), oral drops (20 drops =50 mg), ampoules (100 mg preservative-free, with a shelf-life of five years), dispersable (50 mg) and sustained release tablets (100, 150, and 200 mg), or adult rectal suppositories (100 mg up to four times daily) and paediatric suppositories (15, 30 and 50 mg) 2 . The capsules (onset of action 20 to 40 min) and oral drops are administered three to four times daily and the sustained release tablets twice daily (onset of action 60 min) 2 . Intravenous injections should be given slowly over two to three minutes to minimize side-effects (such as transient haemodynamic instability) and in appropriate dosage titrated to pain severity and patient response 2 .
ADVERSE EFFECTS
Tramadol causes a minor delay in colonic transit, but has no effect on upper gastro-intestinal transit or gut smooth muscle tone 38 . Its intestinal action is mediated mainly peripherally through the enteric opioid and serotonergic systems 2 . It has no significant effect on the sphincter of Oddi or intrabiliary pressure, and has weak spasmolytic properties 3 . Constipation is thus reported to a lesser extent than with other opioids 2 .
Adverse events of tramadol from different routes of administration are comparable 2 . Data from shortterm multiple dose studies show tramadol most commonly causes nausea, tiredness, vomiting, sweating, drowsiness and postural hypotension 39 . Hypotension and orthostatic hypotension occasionally occur after IV administration secondary to peripheral vasodilatation 2 . This can be limited by injecting the drug slowly over several minutes or limiting the size of the bolus dose 2 . Urinary retention occurs less commonly when compared to potent opioids 2 . An open phase IV study using all the formulations of tramadol in 7198 patients with over 100 different pain indications showed adverse events in 16.8% of patients (68.9% were slight, 22.1% were severe) 40 . The most common adverse events were: dizziness (5.3%), central nervous system effects/incoordination (7.1%); nausea (4.8%); autonomic system disorders (3.3%), dry mouth (2.2%) and sedation (2.4%) 40 . The incidence of nausea is lowest after oral administration and highest in PCA administration 2 . A post-marketing surveillance survey studied 7710 patients with acute and chronic pain, treated with sustained-release tramadol, in a mean (usually twice) daily dose of 202.4 mg 41 . Adverse effects occurred in 5.9% of patients, most typically nausea, dizziness and muzziness 41 . The mean onset of analgesia was 35 minutes and the duration, an average of nine hours 41 . Over 80% of patients described the analgesic effect as good or very good 41 . A very recent post-marketing surveillance study of sustained-release tramadol (100, 150, and 200 mg) evaluated 3153 patients in acute and chronic pain 42 . Adverse events occurred in 6.5% of patients and included nausea (3.4%), dizziness (1.5%) and vomiting (1.1%). The mean daily dose was 236 mg (usually in two doses) with good or very good analgesia reported by 82.5% of patients 42 . Tramadol produces naloxone-reversible muscle rigidity at doses higher than the therapeutic dose 43 . The estimated incidence of anaphylactoid or anaphylactic reactions to tramadol is 1 in 700,000 44 . In cardiovascular risk patients, tramadol seems to offer some advantages due to its minor cardiovascular and respiratory side-effects 45 . The value of tramadol in pain states from ophthalmic origin has yet to be fully clinically established 46 .
In all areas of practice, the adverse event profile of tramadol, in a dose-response fashion, is a mixture of opioid (dyspepsia, nausea, vomiting, tiredness, drowsiness) and monoaminergic (headache, dizziness, sweating, dry mouth) effects 47, 48 . Tramadol is associated with a low incidence of cardiac depression, and significantly less dizziness and drowsiness than morphine 4 . Side-effects predominate in one or other of the enantiomers and partly antagonize each other, reducing the severity of side-effects seen in the racemic mixture 2 . By comparison to other strong analgesics, the incidence of adverse events is lower and many of these events can either be prevented or readily treated [49] [50] [51] . In children, the incidence of adverse events with tramadol is much less than in adults 52 . Tramadol has not been associated with clinically significant side-effects such as respiratory depression, constipation, or sedation 5 . Tolerance and psychological dependence have not been a problem in the long-term 32 . One of the more outstanding aspects of tramadol is the extremely low liability to produce clinically relevant respiratory depression, which is negligible in comparison with other opioids used for postoperative pain management [53] [54] [55] . Both tramadol and M1 do, however, depress laryngeal activity (the cough reflex) 2 .
Particularly in the therapy of chronic pain, the commencement of dosage at a low level, with gradual increase, frequently prevents the onset of adverse events, especially in the elderly 56 . Therapy is best commenced at 50 mg three times daily, and gradually increasing until analgesia is achieved (the start low, go slow principle). This results in a low incidence of side-effects and rapidly creates tolerance to them 6, 56, 57 . Nausea and vomiting can be treated with antiemetics (e.g., phenothiazine dopamine antagonists) 6, 58 . The use of ondansetron fails to reduce the nausea associated with tramadol 59 . Concerning side-effects, the rank order is (-) enantiomer > (+) enantiomer > racemate, proving the racemate to be superior in this respect 3 .
Like other opioids, tramadol may induce seizures, especially when used in the presence of proconvulsive drugs (such as monoamine oxidase inhibitors and the tricyclic and selective serotonin uptake inhibitor antidepressants) and it should be avoided in these cases and in epilepsy 1,2,60,61 . By increasing central nervous cathecholamines, tramadol may cause convulsions in susceptible patients, and should be used with caution in patients with head injuries 2 . The reported rate of convulsions with tramadol by the Committee on Safety of Medicines in the United Kingdom is 1 in 7000, with most cases involving interaction with proconvulsive agents or large IV tramadol doses 6, 62 . Much of the toxicity in tramadol overdose appears attributable to the monoamine uptake inhibition rather than its opioid effects 63 . There is no risk of idiopathic convulsions with tramadol alone 6, 64 . Agitation, tachycardia, confusion and hypertension suggest a possible mild serotonin syndrome 63 . A serotonin syndrome may occur with the concomitant administration of tramadol with sertraline 34 .
In moderate overdose situations, cerebral depression, muscular spasms and opisthotonos without cardiovascular or respiratory depression can occur 2 . In acute toxicity studies, lethal dose (LD) 50 values of tramadol are estimated to be around 300-350 mg/kg body weight (rat, mouse, oral administration) 65 . After acute IV administration, the LD 50 values range from 50-100 mg/kg body weight 65 . In subacute and chronic toxicity studies, clinical signs of intoxication are mainly behavioural disorders and convulsions, beginning at dose levels of 25 mg/kg 65 . Reports of deaths involving tramadol alone with associated tissue concentrations are rare 66 . In each tissue or fluid (except urine), the tramadol concentration was found to be greater than the metabolites M1 and M2 66 . Patients with acute porphyrias may, however, be at a greater risk for developing porphyric attacks when treated with tramadol, due to the highest level of porphyrin accumulation compared with other analgesics 67 .
There has been failure to confirm the prolongation of the International Normalized Ratio (INR) due to the interaction of tramadol with coumarin anticoagulants 7 .
There is a low magnitude and frequency of withdrawal signs when daily treatment with tramadol is discontinued 3 . Tramadol fails to precipitate withdrawal in morphine-treated subjects or to attenuate withdrawal in morphine-deprived subjects 3 . It is hypothesized that minimal tolerance, reduced dependence and abuse liability occur because of a unique combination of pharmacological actions; namely, the low affinity and efficacy at the mu-opioid receptors, the slow onset of action and the blockade of noradrenaline reuptake 3 . The frequency of euphoria and dysphoria with tramadol are negligible 11 . It thus has pharmacodynamic and pharmacokinetic properties that are highly unlikely to lead to dependence 1 . Epidemiological data, controlled clinical studies and post-marketing surveillance studies have all confirmed extremely low liability for the development of tolerance and dependence 1,3,68,69 . Tramadol neither produced morphine-like effects nor precipitated a withdrawal syndrome in volunteers on a methadone maintenance program, and is not an attractive substance for abuse or as an opioid substitute 2, 70 . Clinical studies tend to demonstrate no significant precipitated withdrawal signs and minimal dose escalation 2 .
In the United States, the abuse potential is less than one in 100,000 6, 71 . This may result in the greater acceptance of tramadol among health care professionals who have concerns about long-term treatment with morphine-like opioids 3 .
CLINICAL USE (a) Acute Pain
Tramadol has been well evaluated in all the surgical fields, including cardiothoracic 72, 73 , orthopaedic 49, 74 , general [75] [76] [77] and paediatric surgery [78] [79] [80] [81] . Tramadol has been varyingly described as having a potency ranging between 1/5 to 1/20 that of morphine 6, 27, 74 . It is thus a unique central-acting opioid analgesic with, in general, analgesic efficacy and potency comparable to pethidine 22, 32 .
Clinically, in the acute situation, tramadol compares favourably with a range of analgesic agents from paracetamol to morphine, in terms of both efficacy and adverse event occurrence. Analgesic intervention with oral tramadol is of proven value 82 . Comparative studies have generally shown tramadol to be more effective than oral agents such as nonsteroidal anti-inflammatory agents (NSAIDs), pentazocine, dextropropoxyphene and combination formulations containing paracetamol, although single-dose oral dextropropoxyphene 65 mg plus paracetamol 650 mg was found to have a similar analgesic efficacy to tramadol 100 mg 4, 49, [83] [84] [85] .
In both in-patient and day-case studies, intraopera-tive tramadol analgesia has not been associated with cardiorespiratory side-effects or accidental awareness, probably because tramadol does not antagonize the hypnotic effects of the volatile inhalational agents 6, 72, 82, [86] [87] [88] [89] [90] . Tramadol does not cause clinically significant lightening of anaesthesia or recall of intraoperative music during moderately deep isoflurane/ nitrous oxide anaesthesia 87, 91 . Parenteral administration has mainly been associated with postoperative pain management. Given intravenously, tramadol doses ranging from 50 to 400 mg produce analgesia 2, 8, 32 . Postoperatively, an initial intravenous loading dose of tramadol 3 mg/kg, followed by 50 mg every 10 to 20 minutes up to a maximum of 250 mg in the first hour, and 600 mg in 24 hours, may be given 8 . Its intravenous use has recently been compared to epidural morphine for immediate post thoracotomy pain, where a single IV bolus of tramadol was as effective as the epidural morphine bolus and infusion 72 . As a standard dose, tramadol 3 mg/kg, given at induction of anaesthesia, does not obtund the pressor response (for which a short-acting potent opioid should be used), because its onset time is relatively slow 2, 6, 25, 92 . In contrast to postoperative bolus administration, this may allow the patient to awake pain-free with a low incidence of side-effects (nausea, dizziness) 2,6 . A 3 mg/kg IV dose appears to be the most suitable for acute pain of moderate to severe intensity and it causes minimal respiratory depression 6, 93, 94 .
Tramadol has shown comparative efficacy when used as a continuous IV infusion 75, 95 . A postintubation bolus of 1.0 mg/kg followed by a continuous infusion of tramadol (2.5 mg/ml at 15 ml/h titrated postoperatively up or down in 3 ml/h increments based on haemodynamic and respiratory criteria), has been compared with morphine infusion in a tramadol:morphine dose ratio of 16:1. Pain scores were not significantly different and patients receiving tramadol had significantly improved oxygen saturation and higher respiratory rates 96 . It has been suggested that after six hours of continuous infusion, the rate be reduced in order to prevent unnecessary over-administration 75 . Parenterally, tramadol has been found to be effective for moderately severe pain after a loading dose of 150-250 mg and up to 600 mg/day 2 .
Postoperatively, intravenous and intramuscular tramadol has been used with good efficacy in moderate surgical pain 53 97 . Although predominantly mild in nature, the most commonly reported side-effects were headache, nausea, vomiting, dizziness and somnolence 47 . These were significantly higher after dental surgery, possibly as a result of acute dosing of awake patients and rapid patient mobilization 47 .
Following abdominal surgery, tramadol has been found to be similar in efficacy to morphine for postoperative pain relief 98 . After abdominal hysterectomy, 48 h postoperative infusions of tramadol and morphine showed equal analgesic efficacy 99 . No somatic or visceral sensitization was evident during the infusions 99 . After lower abdominal surgery, IV tramadol produces a significantly lower incidence of arterial hypoxaemia than IV morphine 93 . However, when used in combination with other central nervous system depressants (e.g., other opioids), respiratory changes may be seen 2,3 .
Tramadol appears to lend itself particularly to use in the day-case surgical environment 100 . Its efficacy and safety is most appropriate for a combined preoperative, perioperative and postoperative sequence 76, [101] [102] [103] [104] . It provides analgesia with little or no anxiolysis when used as a premedicant 2 . In groin incision day-case surgery, intraoperative and postoperative tramadol gave superior pain relief when compared with intraoperative fentanyl and postoperative co-codamol 2,6,88 . Tramadol shows analgesic dose-response in postoperative and dental pain patients 47 . Oral tramadol is effective for the relief of acute dento-alveolar surgical pain, although the addition of tramadol to diclofenac results in no useful improvement in analgesia 59, 105, 106 . In day-case laparoscopic sterilization, patients receiving IV tramadol 1.5 mg/kg showed significantly less pain in the recovery room and at discharge when compared with IV ketorolac 10 mg 107 . For acute treatment of mild to moderate postoperative pain, frequent nausea and vomiting from tramadol 100 mg suppositories make these less suitable than paracetamol/ codeine suppositories 108 .
Tramadol has also shown good efficacy in IV patient controlled analgesia (PCA) 1, 76, 90 and in subcutaneous PCA 74, 109 , with wide individual variation. Using a loading dose of 40 mg, demand doses of 20 mg and lock-out time of 5 min after major orthopaedic surgery, subcutaneous PCA resulted in good pain relief with a 20:1 dose ratio of tramadol: morphine 74 . After a loading dose of 200 mg (or titration to an individual loading dose) and incremental doses of 20 mg, IV tramadol PCA is effective in acute pain 9, 10 . Intravenous PCA with tramadol or morphine was found to be equally efficacious in treating pain after laparoscopic cholecystectomy, but only after 90 minutes from the end of surgery 110 .
In orthopaedics, following joint replacement therapy, no significant differences in pain scores or side-effects were found in patients given IM or oral tramadol compared to those receiving IV PCA piritramid 111 . Post-arthroscopy, intra-articular tramadol 10 mg is not as effective as morphine 1 mg 112 . After arthroscopic anterior cruciate ligament reconstruction, IM lornoxicam provided a useful alternative to IM tramadol for postoperative analgesia 113 . Tramadol 1.5 mg/kg IV offers little benefit clinically compared with fentanyl 1.5 µg/kg IV when used at the induction of anaesthesia for day-case arthroscopic surgery 114 .
In paediatric surgery, for moderate to severe pain in patients over the age of 12 months, tramadol has been used effectively in IM or IV doses of 1-2 mg/kg 2, 78, 81 . In one study, 21 infants (3-10 kg) received IV or oral tramadol (1 mg/kg) followed by a continuous IV infusion, without respiratory or cardiovascular side-effects 115 . In the paediatric setting, tramadol, especially in droplet form 116 , has real potential as a safe and effective agent for the treatment of moderate pain in children more than 12 months old. Tramadol drops 1.5 mg/kg given 30 minutes before multiple dental extractions in children aged four to seven years resulted in significantly better postoperative analgesia, measured up to 120 minutes postoperatively 117 . For hypospadias surgery, tramadol has also been used neuraxially (by caudal epidural) with a longer duration than that of bupivacaine 6, 118, 119 . In the neonate, however, further pharmacokinetic and clinical studies with tramadol are needed 2 .
In labour, tramadol 100 mg IM has been found to be as effective as pethidine 75 mg IM, but with a superior safety profile without respiratory depression of the neonate 53, 105, 120 . The addition of an antiemetic to tramadol did not reduce the incidence or severity of nausea or vomiting 121 . Tramadol is considered to be non-mutagenic in vivo 122 . The battery of mutagenicity studies show no evidence of genotoxic risk to humans 65 . Reproductive and developmental toxicity investigations and carcinogenicity studies are without positive findings 65 . Tramadol is therefore unlikely to cause damage to germinal cells that could result in birth defects or neoplastic events 122 .
Neuraxially, in epidural administration for pain after abdominal surgery, tramadol is a more effective analgesic than bupivacaine, but less effective than morphine 105 . Epidural tramadol has been given, without respiratory depression, for postoperative pain after caesarean section 123 . The mean time to first analgesic administration was 4.5 (±3.1) h in patients receiving epidural tramadol 100 mg, compared to 6.6 (±3.4) h in those receiving epidural tramadol 200 mg 123 . Tramadol is not, however, recommended for epidural use, due to lack of preclinical neurotoxicity data and the fact that doses required are similar to those of less invasive routes 2 . When administered intrathecally in rodents, the antinociceptive potency of tramadol followed a rank order of racemate > (+) enantiomer > (-) enantiomer 3 . Using an isobolic plot, a synergistic interaction of the isomers could be proven 3 . Tramadol 1 mg/kg IV has been successfully used to treat postoperative shivering 124 . Intravenous tramadol 0.25 mg/kg and 0.5 mg/kg is effective in treating intraoperative shivering during regional anaesthesia for caesarean section 125 . The admixture of tramadol 100 mg with mepivacaine 1% for brachial plexus block provides a pronounced prolongation of blockade without side-effects, supporting a peripheral analgesic effect of tramadol 126 . Tramadol is effective in the treatment of acute ureteric colic (1 mg/kg subcutaneously), acute trauma 53, 127 and pain from myocardial ischaemia 53 . However, following acute myocardial infarction, IV tramadol 50 mg or 100 mg results in a significant decrease in left ventricular stroke wall index (LVSWI) and cardiac index 128 . Although tramadol is usually associated with haemodynamic stability, transient haemodynamic effects have been seen after IV injection 8 .
(b) Chronic Pain
In the treatment of chronic pain, tramadol has been shown to be effective across a wide range of conditions, as might be predicted based on its modes of analgesic action 6 . Examples include chronic pancreatitis 2 , neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia) [129] [130] [131] and rheumatology (osteoarthritis, fibromyalgia) [132] [133] [134] . Tramadol is also effective when making use of differing routes (orally and intra-articularly) 6, [131] [132] [133] [134] . In the rat model, tramadol inhibits acute and chronic inflammation without affecting immune mechanisms 135 . Intraarticular tramadol 50 mg provided significantly better analgesia (a mean duration of five days) than placebo in the treatment of osteoarthritis of the ankle, knee and hip joints 133 . In the treatment of osteoarthritis, tramadol appears preferable to pentazocine and dextropropoxyphene 84, 136 . The addition of tramadol 200 mg/day allows a significant reduction in naproxen dosage without compromising pain relief 137 and it may have a role as adjunctive treatment for breakthrough pain in patients receiving NSAID therapy for osteoarthritis 138 . An open study has shown tramadol to be of use in the treatment of the restless legs syndrome, but controlled studies are needed 139 .
In chronic painful conditions, its reduced constipating effect is an advantage when compared to other opioids 6, 140 . The oral sustained release preparation improves patient compliance and reduces sideeffects 6, 141 . In chronic low back pain, there is equivalence of efficacy and tolerability of twice daily tramadol 100 mg sustained release capsules and four times daily tramadol 50 mg capsules 142 . Tramadol has also proved effective in chronic pain of vascular origin (e.g., scleroderma) 143 .
(c) Cancer Pain
For the treatment of cancer pain, tramadol has been found to be efficacious over a wide range of cancer pain syndromes, with a better side-effect profile and tolerability compared with morphine, and it now occupies step II of the World Health Organisation ladder 1,2 . For Step I treatment, an NSAID±paracetamol can be used, adding or substituting tramadol for inadequate analgesia or NSAID intolerance 2, 144 . Overall however, in the initial treatment, morphine has been more effective for severe cancer pain (which may reflect tramadol's slower onset) 2 .
In both cancer and non-cancer pain, tramadol was shown to have a comparable analgesic effect to morphine and other commonly used analgesic agents, while causing significantly fewer adverse events 56, 57, 68, 132, [145] [146] [147] [148] [149] . Its role in the long-term management of the various types of intractable pain remains to be more accurately described 6 .
CONCLUSION
The advantages of tramadol over traditional opioids are the minimal potential for tolerance (and limited cross-tolerance with morphine), for addiction and for respiratory depression 2 . Even in healthy volunteers, it exhibits little effect on breathing and respiratory patterns 150 . Tramadol is a prescriptiononly medicine rather than a drug controlled by a "Misuse of Drugs Act" in most countries, conferring advantages for both inpatient and community use 2, 8, 151 . The most important side-effects of tramadol are nausea and vomiting, but their incidence and severity can often be reduced by intraoperative administration in the surgical patient, by slow dose titration for those with chronic pain and by the administration of a prophylactic antiemetic 2, 4 . A recent study has shown that a slower titration rate improves tolerability in patients who previously discontinued therapy due to nausea and vomiting 152 . The rate of titration of tramadol rather than the target dose was found to be the major determinant of tolerablilty 152 . A slower rate of initiating tramadol therapy (50 mg increments every three days) also improves tolerability and leads to significantly fewer discontinuations due to dizziness or vertigo 153 .
Tramadol is a central-acting analgesic which has been shown to have dose-related efficacy and to be well tolerated 1 . It appears to be a valuable addition to the analgesic armamentarium as a safe and effective agent across a wide spectrum of acute and chronic painful conditions. It has no major organ toxicity 6, 154 . When compared to the NSAIDs, it does not aggravate hypertension, provoke asthma, gastrointestinal mucosal damage, renal impairment or congestive heart failure 8, 151, 155 . It is of particular value in treating the elderly and in day-case surgery 6 . When compared with other opioids, it does not induce significant respiratory depression, constipation, histamine release, cross-tolerance or have significant abuse potential 8, 151 . It thus confers enhanced safety 2 . Tramadol's lack of gastrointestinal side-effects and its reduced constipation effects (compared with other opioids) gives it great value for prolonged use 2,140 . Tramadol's efficacy over a wide range of acute and chronic pain states, its multi-formulation availability, and its low serious side-effect potential at high doses and in prolonged therapy, combine to bestow on it a user-friendly profile, for short-and long-term use in hospitals and communities 2 .
The unique composition of this agent, with its triple action accompanied by minimal side-effects, will promote further research in this area 3 . The time is ripe to undertake further steps in order to design the next generation of tramadol by fitting together all the knowledge that has been obtained by a subtle step-by-step follow up of this analgesic 3 . A series of compounds related to tramadol has been prepared by linking one of the N-methyls to the 3-position of the cyclohexane ring (Carson JR, 1999-unpublished data). These 4-aryloctahydroisoindoles showed antinociceptive effects in rats and mice. They do not bind to the mu-opioid receptor, nor does their activity parallel their effects on monoamine reuptake. But meanwhile the time has come to take a new look at tramadol itself!
